Viking Therapeutics, Inc.VKTXEarnings & Financial Report
Nasdaq
VKTX Q4 2025 Key Financial Metrics
Revenue
$0
Gross Profit
N/A
Operating Profit
$-164.7M
Net Profit
$-157.7M
Gross Margin
N/A
Operating Margin
N/A
Net Margin
N/A
YoY Growth
N/A
EPS
$-1.39
Viking Therapeutics, Inc. Q4 2025 Financial Summary
Viking Therapeutics, Inc. reported revenue of $0 for Q4 2025, with a net profit of $-157.7M (N/A margin). Cost of goods sold was N/A, operating expenses totaled N/A.
Key Financial Metrics
| Total Revenue | $0 |
|---|---|
| Net Profit | $-157.7M |
| Gross Margin | N/A |
| Operating Margin | N/A |
| Report Period | Q4 2025 |
Viking Therapeutics, Inc. Annual Revenue by Year
Viking Therapeutics, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $0).
| Year | Annual Revenue |
|---|---|
| 2025 | $0 |
| 2024 | $0 |
| 2023 | $0 |
| 2022 | $0 |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| YoY Growth | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $967.5M | $946.8M | $937.9M | $908.3M | $867.0M | $827.9M | $739.4M | $715.7M |
| Liabilities | $33.6M | $25.9M | $26.4M | $28.0M | $20.1M | $32.4M | $26.4M | $76.7M |
| Equity | $933.9M | $921.0M | $911.4M | $880.3M | $846.9M | $795.5M | $713.0M | $639.1M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-6.1M | $-28.5M | $-22.0M | $-31.2M | $-52.3M | $-47.1M | $-94.0M | $-85.3M |